Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer : Multicenter retrospective analysis in South Korea
© 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd..
BACKGROUND: About 3%-5% of non-small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK-positive NSCLC. This study aimed to analyze the real-world efficacy and outcome when administered crizotinib, the first approved target agent for ALK-positive NSCLC, according to first- or late-line treatment.
METHODS: A total of 290 patients with ALK-positive advanced NSCLC who were treated with crizotinib in 15 institutions in South Korea from January 2009 to December 2018 were enrolled.
RESULTS: The median age of patients was 57.0 years, and 50.3% were male. The median follow-up duration was 29.3 months. Among them, 113 patients received crizotinib as first-line therapy. The objective response rate (ORR) was 60.1% (57.0% for first-line recipients, 61.8% for second-/later-line). Median (95% CI) progression-free survival (PFS) was 13.7 (11.6-17.0) months. For first-line recipients, overall survival (OS) was 26.3 (17.6-35.0) months. No significant difference in ORR, PFS and OS, according to the setting of crizotinib initiation, was observed. In a multivariate Cox regression analysis, old age, male gender, initially metastatic, and number of metastatic organs were associated with poor PFS and OS. The most common adverse events were nausea and vomiting, and severe adverse event leading to dose adjustment was hepatotoxicity.
CONCLUSIONS: ORR, PFS, OS, and adverse event profiles were comparable to previous clinical trials. Our findings could aid in the efficient management of ALK-positive lung cancer patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Thoracic cancer - 15(2024), 6 vom: 23. Feb., Seite 448-457 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jeon, Da Som [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1759-7714.15213 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366621580 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366621580 | ||
| 003 | DE-627 | ||
| 005 | 20240229154818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1759-7714.15213 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM366621580 | ||
| 035 | |a (NLM)38171544 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jeon, Da Som |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer |b Multicenter retrospective analysis in South Korea |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND: About 3%-5% of non-small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK-positive NSCLC. This study aimed to analyze the real-world efficacy and outcome when administered crizotinib, the first approved target agent for ALK-positive NSCLC, according to first- or late-line treatment | ||
| 520 | |a METHODS: A total of 290 patients with ALK-positive advanced NSCLC who were treated with crizotinib in 15 institutions in South Korea from January 2009 to December 2018 were enrolled | ||
| 520 | |a RESULTS: The median age of patients was 57.0 years, and 50.3% were male. The median follow-up duration was 29.3 months. Among them, 113 patients received crizotinib as first-line therapy. The objective response rate (ORR) was 60.1% (57.0% for first-line recipients, 61.8% for second-/later-line). Median (95% CI) progression-free survival (PFS) was 13.7 (11.6-17.0) months. For first-line recipients, overall survival (OS) was 26.3 (17.6-35.0) months. No significant difference in ORR, PFS and OS, according to the setting of crizotinib initiation, was observed. In a multivariate Cox regression analysis, old age, male gender, initially metastatic, and number of metastatic organs were associated with poor PFS and OS. The most common adverse events were nausea and vomiting, and severe adverse event leading to dose adjustment was hepatotoxicity | ||
| 520 | |a CONCLUSIONS: ORR, PFS, OS, and adverse event profiles were comparable to previous clinical trials. Our findings could aid in the efficient management of ALK-positive lung cancer patients | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a anaplastic lymphoma kinase | |
| 650 | 4 | |a crizotinib | |
| 650 | 4 | |a non-small cell lung carcinoma | |
| 650 | 4 | |a progression-free survival | |
| 650 | 7 | |a Crizotinib |2 NLM | |
| 650 | 7 | |a 53AH36668S |2 NLM | |
| 650 | 7 | |a Anaplastic Lymphoma Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 700 | 1 | |a Park, Cheol-Kyu |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seung Joon |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Chan Kwon |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Yoon Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Chi Young |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sung Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Shin-Yup |e verfasserin |4 aut | |
| 700 | 1 | |a Ryu, Jeong-Seon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jeong Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Kye Young |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Tae Won |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Seung Hun |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Seong Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sang Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Chang-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyeong Ryul |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yeon Joo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thoracic cancer |d 2010 |g 15(2024), 6 vom: 23. Feb., Seite 448-457 |w (DE-627)NLM251832414 |x 1759-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:6 |g day:23 |g month:02 |g pages:448-457 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1759-7714.15213 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 6 |b 23 |c 02 |h 448-457 | ||